Information
GAITHERSBURG, Md., March 13, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq...
Original sourceAI Summary
Shuttle Pharma raised $5.75 million through a public offering of 19.16 million shares. The offering price was set at $0.30 per share. Funds will advance Phase II clinical trials and marketing efforts. Securities offered under SEC registration effective March 7, 2025. Company focuses on improving radiation therapy outcomes for cancer patients.
Sentiment Rationale
The capital raise supports crucial clinical trials. Past successful offerings often boosted share values as companies advanced their pipeline.
Trading Thesis
Funding will facilitate clinical trials, impacting growth in the long term, similar to successful biotech timelines.
Market-Moving
- Shuttle Pharma raised $5.75 million through a public offering of 19.16 million shares.
- The offering price was set at $0.30 per share.
- Funds will advance Phase II clinical trials and marketing efforts.
Key Facts
- Shuttle Pharma raised $5.75 million through a public offering of 19.16 million shares.
- The offering price was set at $0.30 per share.
- Funds will advance Phase II clinical trials and marketing efforts.
- Securities offered under SEC registration effective March 7, 2025.
- Company focuses on improving radiation therapy outcomes for cancer patients.
Companies Mentioned
- NDAQ (NDAQ)
- SPHR (SPHR)
- PRVB (PRVB)
Corporate Developments
The funding raised is substantial for SHPH's key clinical projects, likely impacting investor confidence.